HIV Infections Clinical Trial
Official title:
HIV Prevalence, Incidence and HSV-2 Prevalence Among High-Risk MSM in Lima, Peru
The purpose of this study is to provide biomedical and behavioral information that is
necessary for planning and starting HIV prevention trials in Lima, Peru.
The occurrence of HIV is high among men who have sex with men (MSM) in Lima, Peru, and
bacterial sexually transmitted diseases (STDs) and HSV-2 (genital herpes) are very prevalent
in HIV-positive and -negative MSM there. Methods to reduce both HIV and STDs are urgently
needed among MSM in Peru. The information gained from this study is very important for
future HIV prevention and vaccine trials that will take place in Peru.
HIV incidence is high among MSM in Lima, Peru, and bacterial sexually transmitted diseases
(STDs) and HSV-2 are prevalent in both recently and chronically HIV-infected MSM as well as
HIV-uninfected MSM. Bisexual HIV-infected MSM could be an important "bridge" transmitting
HIV and other STDs to women. Interventions to reduce both HIV and STDs are urgently needed
among MSM in Peru. Given these associations and the high prevalence of STDs among MSM in
Lima, prevention of HIV infections is dependent partially on innovative methods to control
bacterial and viral STDs among high-risk HIV-uninfected MSM. The data from this prevention
preparedness study is critical for future HIV prevention and vaccine trials that will be
conducted in Peru.
All MSM are counseled and tested for HIV, HSV-2, and syphilis at the screening visit. [AS
PER AMENDMENT 07/23/02: The syphilis test results are provided at screening, whereas the HIV
and HSV-2 test results are provided at the enrollment visit.] High-risk HIV-uninfected MSM
in Lima, Peru, are enrolled. Men are interviewed about risk behaviors in the past 6 months.
Trained counselors provide risk-reduction counseling according to locally accepted
standards. Men are followed at 3-month intervals for 1 year to determine the incidence of
and risk factors for prevalent and incident HIV and HSV-2, and to evaluate the effectiveness
of retention strategies. In the baseline questionnaire, 2 additional modules address sexual
networks and willingness to participate in HIV vaccine or prevention trials, including an
acyclovir trial. Study data are collected and entered into a local database.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |